NCT06274528View on ClinicalTrials.gov

DORA and LP in Alzheimer's Disease Biomarkers

PHASE2RecruitingINTERVENTIONAL
Enrollment

201

Participants

Timeline

Start Date

March 11, 2024

Primary Completion Date

March 11, 2029

Study Completion Date

March 11, 2029

Conditions
Alzheimer Disease
Interventions
DRUG

Lemborexant 10 mg

Within FDA approved dose 10 mg; capsule; QD, 6 month duration

DRUG

Lemborexant 20mg

20 mg; capsule; QD; 6 month duration

DRUG

Placebo

0 mg; capsule; QD; 6 month duration

Trial Locations (1)

63110

RECRUITING

Washington University in St. Louis, School of Medicine, St Louis

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

collaborator

Eisai Inc.

INDUSTRY

collaborator

National Institute on Aging (NIA)

NIH

lead

Washington University School of Medicine

OTHER